ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

cbdMD Launches Max Chill Dragon Fruit D9 Gummies: Your Go-To Relaxation Blend for the Summer

By: Newsfile

Charlotte, North Carolina--(Newsfile Corp. - May 16, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) a leading name in premium CBD offerings, is excited to introduce its newest relaxation innovation: "Max Chill" Dragon Fruit D9 Gummies. Crafted to elevate your summer unwind sessions, these gummies boast a distinctive 1:1 CBD to THC ratio, marking a milestone in the brand's selection of high-mg THC products.

Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, ensuring a balanced experience. This equal ratio harnesses the synergy between THC and CBD to maximize relaxation benefits. CBD's ability to promote relaxation and counteract potential negative sensations associated with THC makes the combination ideal for unwinding and relieving daily stress.

"At cbdMD, we're committed to continually enhancing our customers' journeys, and this new product epitomizes that commitment," expressed Ronan Kennedy, CEO at cbdMD. "We formulated this product with a specific goal in mind: to offer a Farm Bill compliant high mg THC product designed to help reduce daily stress and promote relaxation."

Key Highlights of Max Chill Dragon Fruit D9 Gummies:

  • Balanced Formulation: Each gummy contains a precise 1:1 ratio of 10mg Delta 9 THC and 10mg CBD, offering a harmonious blend for relaxation.
  • Tropical Flavor: Indulge in the tropical taste of dragon fruit, adding a delightful twist to your experience.
  • Vegan and Gluten-Free: Made with vegan-friendly and gluten-free ingredients, catering to diverse dietary preferences.
  • High Potency: Formulated as a new feature in our high mg THC product lineup, providing potent relief.
  • Quality Assurance: Rigorously tested for purity, potency, and safety, ensuring premium quality backed by third-party lab testing.

"We recognize that we have a diverse customer base and some individuals may experience negative side effects with high THC consumption. We were driven to create a product designed to mitigate these effects, targeting a more mellow and tranquil state of mind," continued Kennedy. "Our dedication to providing a premium experience extends to prioritizing our customers' well-being, and we're proud to offer a product that not only delivers on potency but also promotes a positive and enjoyable experience just in time for Summer."

cbdMD's Max Chill Dragon Fruit D9 Gummies retail for $39.99 and are available for purchase at www.cbdmd.com. Must be 21 years or older to purchase. For more information about cbdMD, please visit cbdmd.com or engage with us on social at @cbdmd.usa.

About cbdMD, Inc.:

cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport® products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD's products.

Forward-Looking Statements:

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to federal and state CBD regulation, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO
+1 (704) 445-3064
IR@cbdmd.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209458

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.